Hemostemix Announces Enrollment Update for the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
27 juin 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has enrolled a total of forty (40)...
Hemostemix Announces Convertible Debenture Financing
15 avr. 2019 08h30 HE
|
Hemostemix Inc.
NOT FOR DISTRIBTUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, April 15, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...
Hemostemix Announces Enrollment Milestone in the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
09 avr. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, April 09, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has reached an enrollment...
Hemostemix Announces Appointment of Experienced Chief Medical Officer & President
01 avr. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D,...
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
25 févr. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
Hemostemix Announces Submission of Orphan Drug Designation Application to the FDA
04 févr. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing...
PacketExpert™ APIs for Test Automation and Remote Access
29 janv. 2019 11h13 HE
|
GL Communications Inc.
GAITHERSBURG, Md., Jan. 29, 2019 (GLOBE NEWSWIRE) -- GL Communications Inc. a global leader in telecom test and measurement solutions, announced today its Test Automation and Remote Testing through...
Hemostemix Provides Highlights of 2018 Accomplishments
17 janv. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on...
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
03 janv. 2019 08h00 HE
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
09 nov. 2018 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...